Cargando…
Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies
Cutaneous adverse drug reactions are commonly seen in patients with anticancer drug treatment. Anticancer drugs, including chemotherapy, target therapy, and recent immunotherapy causing skin reactions ranging from mild skin rash to life-threatening severe cutaneous adverse reactions (SCARs), such as...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5822766/ https://www.ncbi.nlm.nih.gov/pubmed/29577050 http://dx.doi.org/10.1155/2018/5376476 |
_version_ | 1783301747877347328 |
---|---|
author | Ng, Chau Yee Chen, Chun-Bing Wu, Ming-Ying Wu, Jennifer Yang, Chih-Hsun Hui, Rosaline Chung-Yee Chang, Ya-Ching Lu, Chun-Wei |
author_facet | Ng, Chau Yee Chen, Chun-Bing Wu, Ming-Ying Wu, Jennifer Yang, Chih-Hsun Hui, Rosaline Chung-Yee Chang, Ya-Ching Lu, Chun-Wei |
author_sort | Ng, Chau Yee |
collection | PubMed |
description | Cutaneous adverse drug reactions are commonly seen in patients with anticancer drug treatment. Anticancer drugs, including chemotherapy, target therapy, and recent immunotherapy causing skin reactions ranging from mild skin rash to life-threatening severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrosis (TEN) with increase morbidity and mortality while they are receiving cancer treatments, have been proposed to be a result of direct skin toxicity or drug hypersensitivity reactions (these are proposed mechanism, not definite). Differentiating SCARs from other more commonly seen reactions with a better outcome help prevent discontinuation of therapy and inappropriate use of systemic immunosuppressants for presumable allergic reactions, of which will affect the clinical outcome. In this article, we have reviewed published articles from 1950 to August 2017 for SJS/TEN associated with anticancer drugs, including chemotherapy, targeted therapy, and immunotherapy. We aimed to provide an overview of SJS/TEN associated with anticancer drugs to increase clinician recognition and accelerate future studies on the pathomechanism and managements. |
format | Online Article Text |
id | pubmed-5822766 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-58227662018-03-25 Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies Ng, Chau Yee Chen, Chun-Bing Wu, Ming-Ying Wu, Jennifer Yang, Chih-Hsun Hui, Rosaline Chung-Yee Chang, Ya-Ching Lu, Chun-Wei J Immunol Res Review Article Cutaneous adverse drug reactions are commonly seen in patients with anticancer drug treatment. Anticancer drugs, including chemotherapy, target therapy, and recent immunotherapy causing skin reactions ranging from mild skin rash to life-threatening severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrosis (TEN) with increase morbidity and mortality while they are receiving cancer treatments, have been proposed to be a result of direct skin toxicity or drug hypersensitivity reactions (these are proposed mechanism, not definite). Differentiating SCARs from other more commonly seen reactions with a better outcome help prevent discontinuation of therapy and inappropriate use of systemic immunosuppressants for presumable allergic reactions, of which will affect the clinical outcome. In this article, we have reviewed published articles from 1950 to August 2017 for SJS/TEN associated with anticancer drugs, including chemotherapy, targeted therapy, and immunotherapy. We aimed to provide an overview of SJS/TEN associated with anticancer drugs to increase clinician recognition and accelerate future studies on the pathomechanism and managements. Hindawi 2018-01-17 /pmc/articles/PMC5822766/ /pubmed/29577050 http://dx.doi.org/10.1155/2018/5376476 Text en Copyright © 2018 Chau Yee Ng et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Ng, Chau Yee Chen, Chun-Bing Wu, Ming-Ying Wu, Jennifer Yang, Chih-Hsun Hui, Rosaline Chung-Yee Chang, Ya-Ching Lu, Chun-Wei Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies |
title | Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies |
title_full | Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies |
title_fullStr | Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies |
title_full_unstemmed | Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies |
title_short | Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies |
title_sort | anticancer drugs induced severe adverse cutaneous drug reactions: an updated review on the risks associated with anticancer targeted therapy or immunotherapies |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5822766/ https://www.ncbi.nlm.nih.gov/pubmed/29577050 http://dx.doi.org/10.1155/2018/5376476 |
work_keys_str_mv | AT ngchauyee anticancerdrugsinducedsevereadversecutaneousdrugreactionsanupdatedreviewontherisksassociatedwithanticancertargetedtherapyorimmunotherapies AT chenchunbing anticancerdrugsinducedsevereadversecutaneousdrugreactionsanupdatedreviewontherisksassociatedwithanticancertargetedtherapyorimmunotherapies AT wumingying anticancerdrugsinducedsevereadversecutaneousdrugreactionsanupdatedreviewontherisksassociatedwithanticancertargetedtherapyorimmunotherapies AT wujennifer anticancerdrugsinducedsevereadversecutaneousdrugreactionsanupdatedreviewontherisksassociatedwithanticancertargetedtherapyorimmunotherapies AT yangchihhsun anticancerdrugsinducedsevereadversecutaneousdrugreactionsanupdatedreviewontherisksassociatedwithanticancertargetedtherapyorimmunotherapies AT huirosalinechungyee anticancerdrugsinducedsevereadversecutaneousdrugreactionsanupdatedreviewontherisksassociatedwithanticancertargetedtherapyorimmunotherapies AT changyaching anticancerdrugsinducedsevereadversecutaneousdrugreactionsanupdatedreviewontherisksassociatedwithanticancertargetedtherapyorimmunotherapies AT luchunwei anticancerdrugsinducedsevereadversecutaneousdrugreactionsanupdatedreviewontherisksassociatedwithanticancertargetedtherapyorimmunotherapies |